ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference

Rhea-AI Summary

ORIC Pharmaceuticals, a clinical-stage oncology company, will have its CEO, Jacob Chacko, present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 11:00 am ET. The company focuses on developing therapies to combat therapeutic resistance in cancer. Its lead candidate, ORIC-101, is currently undergoing Phase 1b trials in conjunction with Xtandi and Abraxane. A webcast of the presentation will be available via the investor section of their website, with a replay accessible for 90 days afterward.

SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 11:00 am ET.  

A webcast of the presentation will be available through the investor section of the company’s website at https://investors.oricpharma.com/. A replay of the webcast will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.  ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.  Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to http://oricpharma.com/.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

When will ORIC Pharmaceuticals CEO present at the Jefferies Virtual Healthcare Conference?

Jacob Chacko, CEO of ORIC Pharmaceuticals, will present on June 2, 2020, at 11:00 am ET.

What is ORIC-101 and its significance in ORIC Pharmaceuticals' trials?

ORIC-101 is the lead candidate of ORIC Pharmaceuticals, currently in Phase 1b trials to address resistance in metastatic prostate cancer and other solid tumors.

Where can I watch the presentation of ORIC Pharmaceuticals at the Jefferies Conference?

The presentation can be viewed through the investor section of ORIC Pharmaceuticals' website.

How long will the ORIC Pharmaceuticals presentation be available for replay?

The replay of the presentation will be available for 90 days following the event.

What is the focus of ORIC Pharmaceuticals as a company?

ORIC Pharmaceuticals specializes in developing treatments that overcome resistance mechanisms in cancer therapies.